BioTech Report
Rick Currin, Editor, Currin BioTech Newsletter
Special Investor's Report from the investment newsletter legend who has been ranked No. 1 by The Hulbert Financial Digest a remarkable five times.
The Coming Big Pharma Meltdown: An $8.3 billion market disrupted

7 Surprising Reasons This biotech stock could triple in 2015.

    Dear Investor,

    Over 334 million Americans take prescription pain medicine – drugs that come with terrible side effects and addiction.

    Take OxyContin®, for example. The prescription drug produces $2,535,000 in U.S. sales alone.

    Currin believes a new pain breakthrough could be a disruptive force.

    "Investors," he notes, "should know that OxyContin®, Vicodin®, Lidoderm®, Fentanyl® and Opana ER® are in danger of obsolescence."

    And Currin has a long, consistent track record for success.

    Just look at these biotech winners he disclosed to his subscribers:

Company Ticker Gain Months Held
Incyte INCY 405% 48
Pharmacyclics, Inc. PCYC 2,320% 48
Cepheid CPHD 178% 53
Genomic Health GHDX 132% 53
Cellceutix Corp. CTIX 108% 24

   His portfolios have been rated #1 by MarketWatch Hubert Digest Rating Service an incredible 5 times. Now Mr. Currin believes a new pick could do as well or better than anything he’s seen in years.

   Why?

   The 7 surprising reasons are detailed in a free Special Report Innovation for the largest global prescription market – Relmada takes aim at the mega market in pain written by Mr. Currin. Here are the highlights:

Reason #1: Relmada is a disruptive biotech breakthrough.

   Rick Currin always looks for trends...especially something that can change the marketplace for a decade.

   This patented technology could be one of those mega disruptive trends.

   Relmada is revolutionizing the $8.3 billion pain management industry with a pipeline of products, some in late stage trials.

   Relmada's potentially disruptive pain management products could grab a huge share of the market from OxyContin®, Vicodin®, Lidoderm®, Fentanyl® and Opana ER®. It could even make some opioid pain products obsolete.

   These antiquated painkillers have negative side effects, such as:

Constipation
Nausea
Vomiting

   And worse, addiction. Relmada’s patented  product limits these side effects, is less addictive, and is more effective in stopping pain that subscriptions currently written worth billions of dollars.

Reason #2: Huge market and growing demand

   Rick Currin points out that this market is huge – really huge.

   How big?

334 million prescription patients in the U.S., the largest in the world.
1.5 billion worldwide

   Millions visit the doctor's office for pain, more than anything else, including diabetes, heart disease and cancer.

   For doctors and patients, the Relmada alternative is irresistible.

Reason #3: Profitable market

   The pain management market is incredibly profitable – and large.

Just look at these current sales:

Brand Name Product Yearly Sales in Millions
OxyContin® Oxycodone $2,535
Vicodin®* Hydrocodone/APAP $1,051
Lidoderm® Lidocaine patch $948
Fentanyl®* Fentanyl $862
Opana ER® Oxymorphone $386

  That's $4.7 billion in total sales for non-narcotic products. It's $8.3 billion for narcotic product sales, almost double the sales for non-narcotic pain medication.

    And Relmada has solutions for narcotic and non-narcotic products, with fewer side effects...

Reason #4: Comprehensive solution

   Relmada has four products. Each targets different pain management levels.

   All without the terrible side effects of current drugs, fewer addictions and with superior pain management.

Reason #5: The key to success is management

   The management of the company is extremely powerful and effective. Take just the Chief Scientific Officer, Dr. Eliseo Salinas, history of success:

Product Sales Type Peak Sales in Millions
TysabrI® Worldwide $1,631
Sonata® USA $120
Vyvanse® USA $1,228
Lialda® USA & Europe $529
Intuniv® USA $335
Adderall XR® North America $1,102
Fosrenol® Worldwide $441
Daytrana® USA $79
Efexor XR® Worldwide $3,928

   The team is like a who's who in public company success.

Reason #6: Biotech acquisitions

   Currin believes this company will succeed, and its stock could skyrocket with no acquisitions.

   But realistically, the Big Pharma companies that will potentially be hurt by these innovations may attempt to acquire the company – to early investors' advantage.

Reason #7: The company is moving fast for success with special FDA favor

   The disruptive breakthrough should create an amazing opportunity for investors in 2015. The company is on a fast track for FDA approval – not the grueling years and years FDA approval normally takes.

   The FDA granted Relmada a special favor: 505(b)(2) status. It allows Relmada to bring its products to market at lower risk, lower cost, and faster than typical drug development.
2015 should be Relmada's big year, according to Currin.

   Mr. Currin has written a special report on the company for his subscribers, Innovation for the largest global prescription market – Relmada takes aim at the mega market in pain management.

   You can receive a free copy of the report by clicking here. Or you can subscribe to the Currin BioTech Newsletter and get all his winning biotech picks.

   And as a subscriber, you can follow the development of Relmada as Currin monitors the stock's progress for you.

For a special introductory discount, click here.

Click here to subscribe to
Currin BioTech Newsletter
and get your 3 Special Reports
or Call Toll-Free
1-877-654-2246
M-F 7:00 am - 6:00 pm

Bio Tech Stock Spotlight by Rick Currin




Video briefing on why investors trust
Currin BioTECH Newsletter...


 

 

 


The Triumph Investing System triumph-investing-report

This new Special Report explains the TRIUMPH investing system Rick uses to find winning biotech stocks. This proprietary system focuses on:

 Targeting and therapeutic potential, specifically addressing disease populations with unmet medical needs.

 Research. Rick looks for academic, clinical and preclinical evidence that the targeting is likely to produce a successfully marketed drug candidate.

 Institutional interest. The number of researchers and following institutions including Big Pharma companies interested in the target.

 Uniqueness. What sets the company apart? Is it well ahead in a technical area? Is it in an un-crowded space?

 Management. There are many things to look at here including success with other companies in the same area.

 Patents, positioning and personalized.

 Hidden potential.

   Start your risk-free subscription to the Currin BioTech newsletter at a special discount rate and receive a FREE copy of these invaluable Special Reports. Call 877 654 2246, or complete and return this New Member Savings Form .

        

What YOU Should Consider Now:
what-you-should-consider

1. Go online now or call your discount broker to invest in Relmada Therapeutics, Inc. (OTCBB: RLMD).

2. Subscribe now to Currin BioTech Newsletter to follow my buy, hold and sell recommendations for Relmada as well as other stocks.

Click here   or call 1-877-654-2246,
M-F 7:00 am to 6:00 pm


certificate-seal


New Member
Savings Certificate

Currin Technology - 211 West 92nd Street
Chicago, IL 60620 - 1-877-654-2246

red-check-box-pngYES, Rick!

I want to cash in on the biotech megatrends and enjoy consistent double-, triple- and quadruple-digit gains from the technology investments that offer explosive profit potential no matter what direction the market moves.

Sign me up for Currin BioTech Newsletter today!

I get 12 issues filled with your proven analysis and insights... Email Updates... Timely Buy and Sell Signals... Exclusive Special Reports... and 24/7 access to the Members Website with 3 Model Portfolios taking advantage of the 3 most significant developments in biotech...

Plus the Bonus Gifts listed below!

I understand I MUST be absolutely thrilled with everything I receive. If I'm not, I can cancel at any time within 30 days for a prompt, hassle-free refund. And even if I choose to cancel, I don't have to return anything -- any issues and Special Reports I receive are mine to keep no matter what!

STEP #1:
Please select your preferred term.


15 YEARS OF PROFITABLE RESULTS IS PLENTY OF PROOF:
The more access you have to Rick Currin's BioTech Newsletter, the better!

  BEST DEAL -- Get 2 years and SAVE 59%!

Sign me up for 2 years (24 issues) at the special rate of just 289 -- a savings of $411 off the regular price! I'll enjoy all the benefits of the members-only website along with the bonus gifts shown here:

Triumph Investing  (a $30 value)

Complete Strategy Guide to Biotech Investing (a $30 value)

A total value of $760 for $289 -- I save $471

PLEASE CHECK ONE BOX ONLY!
*You do not have to check both boxes.
 (If you qualify for the Senior Discount, simply check "Senior Discount.")


BIGGEST SAVINGS:
      A 2-year (24 issues) subscription.
SENIOR DISCOUNT:
      A 2-year (24 issues) subscription with a senior discount.
      (I certify I am at least 50 years of age. Please be sure to include my special senior discount
      of $10 off the cost of my order.)

  1-YEAR DEAL -- Only $149 -- a Savings of 57%

I prefer your 1-year membership (12 issues) at the special rate of $149 instead.
I SAVE $201 and get all the benefits of the members-only website.

Plus receive a copy of TRIUMPH Investing (a $30 value)

A total value of $380 for $149 -- I save $231

PLEASE CHECK ONE BOX ONLY!
*You do not have to check both boxes.
 (If you qualify for the Senior Discount, simply check "Senior Discount.")


BIG SAVINGS:
      A 1-year (12 issues) subscription.

SENIOR DISCOUNT:
      A 1-year (12 issues) subscription with a senior discount.
      (I certify I am at least 50 years of age. Please be sure to include my special senior discount 
    of $10 off the cost of my order.
)

 

STEP #2:
Fill out the form below
.

    Yes, Rick!  I'm ready to cash in on the biotech megatrends which offer explosive profit potential no matter what direction the market moves. Sign me up for Currin BioTech Newsletter today! I understand that I am fully protected by your Ironclad 100% Money-Back Double Guarantee.

    Please fill in your name and address below.
    We'll ask you to provide
    credit card information on the next page:

    -


  • Should be Empty:

 10-DAY QUICK RESPONSE BONUS:
I'm responding within 10 days. Please send me your complete analysis report, Painkillers & Profits: How Relmada Could Revolutionize Medicine and Make Millions for Shareholders (a $15 value).

This Changes Everything

 

 

        

At Currin BioTech Newsletter, my goal is to make you money and lots of it. So I'm giving you my Ironclad Money-Back Double Guarantee of Satisfaction:





Important Notice and Disclaimer:
Currin BioTech Newsletter is an independent paid circulation newsletter. This online report is a solicitation for subscriptions and a paid promotional advertisement of Relmada Therapeutics, Inc. (RLMD). RLMD was chosen to be profiled after Currin BioTech completed due diligence on RLMD. Currin BioTech Newsletter expects to generate new subscriber revenue, the amount of which is unknown at this time, resulting from the distribution of this report. While receiving no direct compensation, and maintaining absolutely no obligation to provide any future views in support of the company highlighted, Currin BioTech Newsletter will receive indirect marketing support consistent with distribution of the report and will likely acquire new subscribers, the amount of which is not known at this time. Gramercy Strategic Partners paid one hundred, thirty seven thousand, nine hundred dollars to advertising agencies for the cost of creating and distributing this report online, in an effort to build investor awareness. This report does not provide an analysis of a company's financial position, operations or prospects and this is not to be construed as a recommendation by Gramercy Strategic Partners or an offer to buy or sell any security or investment. An offer to buy or sell can only be made with accompanying disclosure documents and only in states and provinces for which they are approved. Do not base any investment decision based solely on information in this report. Although the information contained in this advertisement is believed to be reliable, Gramercy Strategic Partners makes no warranties as to the accuracy of any of the contents herein and accepts no liability for how readers may choose to utilize the content. Readers should perform their own due diligence, including consulting with a licensed, qualified investment professional. Further, readers are strongly urged to independently verify all statements made in this report. RLMD's financial position and all other information regarding RLMD should be verified directly with RLMD. Audited financial statements and other relevant information about RLMD can be found at the Security and Exchange Commission's website at www.sec.gov. It is recommended that any investment in any security should be made only after consulting with your investment advisor and only after reviewing all publicly available information, including the financial statements of the company. The information contained herein contains forward-looking information within the meaning of section 27a of the Securities Act of 1933, as amended, and section 21e of the Securities Act of 1934, as amended, including statements regarding growth of RLMD. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act, statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties. All forward-looking statements are based upon current assumptions that are believed to be reasonable. In the event any such assumptions turn out to be incorrect, forward-looking statements based upon those assumptions will not be accurate. Currin presents information in this online report believed to be reliable, but its accuracy cannot be guaranteed. More information can be found at the Relmada Therapeutics, Inc. website at www.relmada.com.

Privacy Policy: This website uses the Google AdWords remarketing service to advertise on third party websites (including Google) to previous visitors of our site. This could be in the form of an advertisement on the Google search results page, or a site in the Google Display Network. Third-party vendors, including Google, use cookies to serve ads based on someone's past visits to this webpage. These cookies do not in any way identify you or give access to your computer. Any and all data collected will be used in accordance with Google's privacy policy. If you wish to opt out of interest-based advertising entirely by cookie settings, you may do so in the Google Ad Preferences page located at http://www.google.com/settings/ads/onweb/.